UroGen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report sent to investors on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Other research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $64.00 price objective on shares of UroGen Pharma in a research note on Tuesday, February 25th. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $40.00.

UroGen Pharma Price Performance

URGN stock opened at $9.92 on Monday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70. The stock’s 50 day moving average is $10.44 and its two-hundred day moving average is $11.72. The company has a market capitalization of $232.66 million, a PE ratio of -3.15 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Analysts predict that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mark Schoenberg sold 4,551 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of URGN. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the 4th quarter worth about $59,000. Lazard Asset Management LLC bought a new stake in UroGen Pharma during the 4th quarter valued at approximately $67,000. Aquatic Capital Management LLC bought a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $101,000. BNP Paribas Financial Markets lifted its position in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the period. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of UroGen Pharma in the 4th quarter worth approximately $126,000. 91.29% of the stock is owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.